BioLamina CEO Klaus Langhoff-Roos discusses the challenges of scaling stem cell production from lab plates to bioreactors, ...
Biotech funding surges as companies like Pelage, Kardigan, and Kailera secure millions to innovate treatments for hair loss, ...
Bristol Myers Squibb's acquisition of Orbital Therapeutics includes OTX-201, a next-gen CAR T-cell therapy, and a proprietary ...
Jennifer McCollum is President and CEO of Catalyst, a global nonprofit that accelerates progress for women by promoting workplace inclusion. Before joining Catalyst, McCollum was CEO of Linkage, Inc. ...
In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopedics division into a standalone company, the global implications of the Most Favored Nation drug ...
As timelines change, medical affairs teams must adjust their skillsets. Dr. William Soliman: We’ve seen Pfizer doing a deal ...
Hunter Smith,CFO of Rhythm Pharmaceuticals, noted that maintaining balance between investor expectations and long-term ...
President Trump’s latest attempt at implementing International Reference Pricing- based (IRP-) methodology to regulate drug ...
Although specific terms of the collaboration have yet to be disclosed, Nabla Bio detailed in a press release that it is ...
Catherine discusses the recent advancements in neuroscience and rare disease innovation over the past few years. The ...
In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff ...
There’s some strain, and I think it is unfair to the pharma industry to put these kinds of limits and caps on what they’re ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results